Current topics and perspectives relating to hormone therapy for prostate cancer

@article{Suzuki2008CurrentTA,
  title={Current topics and perspectives relating to hormone therapy for prostate cancer},
  author={Hiroyoshi Suzuki and Naoto Kamiya and Takashi Imamoto and Koji Kawamura and Masashi Yano and M Takano and Takanobu Utsumi and Yukio Naya and Tomohiko Ichikawa},
  journal={International Journal of Clinical Oncology},
  year={2008},
  volume={13},
  pages={401-410}
}
Prostate cancer is androgen-dependent, and hormone therapy, mainly achieved by androgen deprivation, has been one of the main treatment modalities in the clinical management of prostate cancer patients for more than six decades. In the 1980s, luteinizing hormonereleasing hormone agonists, which reduce testosterone to castration levels, were introduced Also, after the 1980s, nonsteroidal antiandrogens were developed in addition to steroidal antiandrogens. Since then, so-called maximum androgen… Expand
Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments.
TLDR
The current state of anti-androgen therapy, mainly for CRPC, is detailed, with major emphasis on the most potent and promising compounds under development. Expand
Alternative Antiandrogen Therapy for CRPC
TLDR
Responsiveness to second-line regimens is the most important prognostic factor for increased cause-specific and overall survival and Responders toSecond-line hormonal treatment are expected to survive significantly longer than nonresponders. Expand
Novel strategies in the treatment of castration-resistant prostate cancer (Review).
TLDR
Docetaxel-based chemotherapy regimens significantly improve overall survival (OS) in patients with castration-resistant prostate cancer, and a nuclear factor-β ligand inhibitor, denosumab, has been developed for the treatment of bone metastases. Expand
Additive effect of zoledronic acid on serum prostate‐specific antigen changes for hormone‐sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade
TLDR
The addition of zoledronic acid to combined androgen blockade showed prostate‐specific antigen and bone turnover markers response compared with combined androgens blockade therapy only, suggesting a potential antitumor effect of zolingronic acid in the management of metastatic prostate cancer patients. Expand
Cardiovascular health in men on androgen deprivation therapy for prostate cancer
TLDR
Findings support evidence that diet and exercise can improve general well-being of patients treated with ADT, and provide novel data on the effects of such an intervention on cardiovascular health. Expand
Pregnane X receptor as a therapeutic target to inhibit androgen activity.
TLDR
PXR may represent a novel therapeutic target to lower androgen activity and may aid in the treatment and prevention of hormone-dependent prostate cancer. Expand
Current Treatment Strategies for Castration-Resistant Prostate Cancer
TLDR
Cabazitaxel and sipuleucel-T are now approved for use in metastatic CRPC by the US Food and Drug Administration and some are in phase III development. Expand
Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer
TLDR
ABiraterone acetate was generally well‐tolerated, and the recommended AA dosage regimen in Japanese CRPC patients is 1000 mg oral dose under modified fasting conditions (at least 1 h premeal or 2 h postmeal). Expand
Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model.
TLDR
This predictive nomogram could predict the prostate-specific antigen decrease ≥50% in response to alternative non-steroidal antiandrogen therapy and might be of benefit to determine the sequential treatment strategy in patients with relapse after first combined androgen blockade. Expand
Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients.
TLDR
This review will discuss the clinical trials which have investigated the potential of Gene-directed enzyme prodrug therapy at various stages of prostate cancer progression, as well as some of the recent advances which enhance the potential utility of GDEPT. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 48 REFERENCES
Endocrine treatment of prostate cancer
  • T. Tammela
  • Medicine
  • The Journal of Steroid Biochemistry and Molecular Biology
  • 2004
TLDR
Data support that androgen deprivation is an effective treatment for patients with advanced prostate cancer, however, although it improves survival, it is not curative, and creates a spectrum of unwanted effects that influence quality of life. Expand
Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
TLDR
Subsequent nonsteroidal antiandrogen therapies were effective against prostate cancer relapse after hormonal therapy and support the notion that second line responders are androgen independent but still hormonally sensitive. Expand
Are Non-Steroidal Anti-Androgens Appropriate as Monotherapy in Advanced Prostate Cancer?
TLDR
Preliminary findings indicate that flutamide may be as effective as orchidectomy in terms of prolonging progression-free survival in selected patients and bicalutamide is well tolerated as monotherapy and appears to be aseffective as castration in patients with locally advanced non-metastatic disease. Expand
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer
TLDR
There is an urgent need for new agents that provide palliation and improve survival in men with metastatic prostate cancer, including chemotherapy with docetaxel for patients with CRPC. Expand
Androgen receptor involvement in the progression of prostate cancer.
TLDR
Genetic diagnosis and/or molecular-targeted therapy via AR pathways can be developed for hormone-refractory states and several co-factors between ARs and the transcriptional complex have been cloned and reports indicate that steroid receptor co-activator 1 is correlated with the hormone- Refractory progression of prostate cancer. Expand
Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.
TLDR
Prostate cancer is amenable to control by intermittent androgen suppression and affords an improved quality of life when the patient is off therapy, which results in reduced toxicity and cost of treatment and possibly delays tumor progression. Expand
Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer.
TLDR
Withdrawal responses to agents that act via steroid hormone receptors represent a generalized phenomenon that can result in palliation for patients with hormonally relapsed prostate cancer and a trial of "withdrawal therapy" is warranted in patients with relapsing disease prior to the initiation of more toxic therapies. Expand
Should intermittent androgen deprivation be used in routine clinical practice?
TLDR
There are several unanswered questions regarding this approach, and until more definitive data regarding its safety and impact on survival are available, IAD should be considered experimental. Expand
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
TLDR
Following maximum androgen blockade with an alternative nonsteroidal antiandrogen is effective for advanced prostate cancer that has relapsed after initial maximum androgens blockade, and responders to second line regimens are androgen independent but still hormonally sensitive. Expand
Hormone-refractory (D3) prostate cancer: refining the concept.
TLDR
A new classification of patients based on hormonal sensitivity is proposed to recognize that androgen-independent proliferation, progression of disease despite castrate levels of testosterone, does not necessarily mean that a tumor is refractory to hormonal manipulations. Expand
...
1
2
3
4
5
...